An observational study in Pancreas Cancer, sponsored by University Health Network, Toronto. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by University Health Network, Toronto · Observational
This is a prospective, multi-centre, translational and observational study. Two cohorts of patients with pancreatic ductal adenocarcinoma (PDAC) are eligible to enroll 1) Upfront resectable PDAC 2) Advanced (unresectable PDAC or metastatic). Patients will have tissue either at resection or from a biopsy at enrolment processed for whole genome sequencing, RNA sequencing and for establishment of patient derived organoids (PDOs). Background epidemiological history and outcome data will be prospectively annotated. Serial blood and stool samples will be collected for exploratory analyses. All electronic medical record information will also be collected. Data will be used to determine if an integrated correlative analysis of whole genome sequencing/RNAsequencing (WGS/RNAseq) and PDOs in the enrolled population will increase the number of patients receiving a precision-matched treatment in Ontario
This study is being done to answer the following question: Can creating 3D models using tumour samples and looking at genetic information from pancreatic ductal adenocarcinoma (PDAC) tumours, help us to provide more patients with a specific, personalized treatment? Two groups of patients with PDAC are eligible to enroll 1) PDAC patients that will go straight to surgery 2) PDAC patients where the disease is either too advanced for a surgical option, or the disease has spread to other areas in the body. Patients will have tumour tissue taken either during their surgery or from a biopsy at enrolment. Background history, outcome data, questionnaires, series of blood draws and stool samples will be collected for analyses. All electronic medical record information will also be collected.
Researchers are looking for better ways of understanding and treating pancreatic cancer by looking to see how useful it is to know about changes and characteristics in the genes in the tumour (molecules that contain instructions for the development and functioning of the cells). Results from analyzed data may be useful in choosing treatments for enrolled patients and for patients in the future. Patients current treatment plan will not change if they choose to take part in this study.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →University Health Network, Toronto is the lead sponsor of 1,411 studies on the registry; 292 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Upfront resectable PDAC
Other: Non-interventional
Advanced (unresectable PDAC or metastatic)
Other: Non-interventional
Standard of care intervention
Precision-Matched Treatment Utilization Rate
Number of patients receiving precision-matched treatment in Ontario based on integrated correlative analysis of whole-genome sequencing (WGS), RNA sequencing (RNAseq), and patient-derived organoids (PDOs).
Time frame: 4 years
Build a comprehensive dataset of pancreatic cancer specimens (tissue and blood) and matched patient-derived organoids (PDOs)
Time frame: 4 years
Correlate drug sensitivities in patient-derived organoids (PDOs) and molecular information
Time frame: 4 Years
Correlate immune phenotypes and molecular profiles
Time frame: 4 Years
Develop an electronic medical record (EMR) platform utilizing artificial intelligence (AI) modeling
Time frame: 4 Years
Correlate serial plasma whole-genome sequencing (WGS) and tissue WGS
Time frame: 4 Years
Characterize the epigenome in established patient-derived organoids (PDOs)
Time frame: 4 Years
Assess oncolytic virus efficacy in combination with immune checkpoint inhibitors in a subset of 50 patient-derived organoids (PDOs) co-cultured with autologous peripheral blood mononuclear cells (PBMCs)
Time frame: 4 Years
Identify microbiome differences in patients at various stages of pancreatic ductal adenocarcinoma (PDAC) and their correlation with whole-genome sequencing (WGS)/RNA subtypes
Time frame: 4 Years
Document stroma subtypes in pancreatic cancer and their correlation with clinical outcomes
Time frame: 4 Years
Evaluate treatment responses in patients receiving precision-matched treatment using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Time frame: 4 Years
Investigate the involvement of genetic and environmental factors in the development and progression of pancreatic cancer
Time frame: 4 Years
Assess comparability between WGS and commercial panel
Time frame: 4 Years
Explore the feasibility and efficacy of utilizing digitized whole-slide images of biopsy or resection specimens for an AI-based digital pathology prediction system
Time frame: 4 Years
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto